AUTHORS
Evangelos Terpos, MD, Ioannis Ntanasis-Stathopoulos, MD2, Maria Gavriatopoulou, MD3, Nikolaos Kanellias, MD, PhD4, Panagiotis Malandrakis, MD, MSc, PhD5, Eirini Solia, MD6, Foteini Theodorakakou, MD7, Yagnik Vyas8, Magdalini Migkou9, Evangelos Eleutherakis-Papaiakovou10, Efstathios Kastritis, MD11, Meletios-Athanasios (Thanos) C. Dimopoulos, MD12
AFFILIATIONS
1 National and Kapodistrian University of Athens, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, Athens, Greece
4 National and Kapodistrian University of Athens, Athens, Greece
5 National and Kapodistrian University of Athens, Athens, Greece
6 National and Kapodistrian University of Athens, Athens, Greece
7 National and Kapodistrian University of Athens, Athens, Greece
8 Veeda Lifesciences, Athens, Greece
9 National and Kapodistrian University of Athens, Athens, Greece
10 National and Kapodistrian University of Athens, Athens, Greece
11 National and Kapodistrian University of Athens, Athens, Greece
12 Korea University, Seoul, Korea, Rep. of South, National and Kapodistrian University of Athens, Athens, Greece
ABSTRACT
Introduction The MAIA trial established daratumumab with lenalidomide, dexamethasone (DRd) as standard therapy for transplant-ineligible (TI) NDMM. Belantamab mafodotin (belamaf) showed high efficacy in relapsed/refractory disease. Quadruplet regimens improved clinical outcomes, supporting belamaf + DRd evaluation in TI NDMM.
Methods BelaDRd, a phase 1/2, open-label study (EUCT-2021-006792-42) evaluated this combination in TI, intermediate-fit and frail, NDMM. Part 1 (dose-finding phase) assessed the safety and tolerability of two belamaf doses (1.9/1.4 mg/kg Q8W) with DRd. This part established belamaf 1.9 mg/kg Q8W, extended to Q12W as the recommended phase 2 dose (RP2D). Part 2 (dose-expansion phase) evaluates the safety and efficacy of the RP2D in two randomized cohorts, Groups A and B, where belamaf dosing was guided by ophthalmologist and hematologist decision (using Vision-Related Anamnestic, VRA tool), respectively.
Results At clinical cut off, 15th May 2026, in Part 1, 24 patients (pts) (median age: 73 years; male: 54.2%) entered the study; 12.5% had high-risk cytogenetics (HRC). At a median follow-up of 37.2 months, 18 (75%) pts were on treatment, and 6 (25%) discontinued; 4 (16.7%) death, 2 (8.3%) AE/SAE, 1 (4.2%) withdrew consent, and 1 (4.2%) due to progressive disease (PD). At baseline, 79.2% pts had cataract. Of 419 planned belamaf doses 111 (26.5%) were delayed/skipped due to OAEs. The median dose intensity (MDI) of belamaf was 0.5 mg/kg/Q4W. The overall ORR (≥ PR) was 91.7% (22/24). Sixteen pts (69.6%) achieved ≥CR (≥2 response assessments). MRD negativity was achieved in 14 (87.5%) of evaluable pts (n=16).
In Part 2 (n=12; median age: 74 years; male: 58.3%); 16.7% of pts had HRC. At a median follow-up of 23.4 months, 11 pts (91.7%) remained on treatment; 1 pt (8.3%) discontinued due to PD. Overall 66.7% pts had cataract (Group A: 83.3%; Group B: 50%). Of 142 planned belamaf doses, 15 (10.6%) were skipped due to OAEs. Held doses as a proportion of planned doses was 16.7% (13/78) in Group A and 3.1% (2/64) in Group B. The MDI was 0.8 mg/kg/Q4W. The overall ORR was 91.7% (11/12). Eight patients (66.7%) achieved a response of ≥CR (Group A: 3 pts (50%); Group B:5 pts (83.3%)). MRD negativity was achieved in 6 (50%) of evaluable pts (n=8). The median time to ≥PR was 1.1 months for both parts.
At 18 months, PFS rates were 91.7% (95% CI 76.4–97.2) overall and 87.5% (66.1–95.8) in the RP2D population; corresponding TTP rates were 97.1% (80.9–99.6) and 95.5% (71.9–99.4). Projected mPFS ranged from 104.8-190.8 months (8.7-15.9 years) overall and 89.5-195.0 months (7.4-16.2 years) in theRP2D population.
Grade ≥3 BCVA decline was observed in 85 (10.5%) of ocular assessments in part 1 and 6 (4.3%) and 7 (5.8%) in part 2 groups A and B, respectively. Grade ≥3 OAEs without VRA-reported "substantial time" (>50% of the time) were detected in 1/58 (1.7%) of belamaf dosing cycle ophthalmologist assessments in Group B. Grade ≥2/≥3 keratopathy occurred in 12.7%/0.8% of assessments in Part 1; in Part 2, rates were 6.5%/0% (Group A) and 13.8%/0% (Group B). Median resolution time of ≥Grade 2 BCVA OAE/keratopathy was 1.1/1.0 months (Part 1) and 1.9/1.0 months (Part 2). In Part 1, driving/reading cessation due to eyesight issues occurred in 1.0%/0.4% of assessments and only 0.8% of assessments each in part 2 (Group B). Absence of pt reported blurry vision on VRA was associated with low rates of Grade ≥2 keratopathy (7/145, 4.8%) of assessments, and no grade ≥3 Keratopathy. Grade ≥2/≥3 BCVA was observed in 21/145 (14.5%) and 2/145 (1.4%) of assessments.
Fatal TEAEs were observed in 4 pts in part 1 [febrile neutropenia, cardiac arrest, lower respiratory tract infection and pseudomonal sepsis in 1 (4.2%) each] and none in part 2.
Conclusions BelaDRd induced rapid, deep, and sustained responses, with high MRD-negativity rates and prolonged PFS in intermediate fit and frail patients with TI NDMM. VRA and KVA assessments were highly concordant, with very low number of patients reporting problems in driving and/or reading (<1%). Hematologist-guided ocular assessments resulted in a favorable ocular safety profile, fewer OAE-related dose holds, and faster OAE resolution. These findings support the continued development of BelaDRd as a promising frontline quadruplet regimen for NDMM, while reducing reliance on ophthalmologic examination.
Funding by GSK (NCT05280275); authors solely responsible for content.
DISCLOSURES
Evangelos Terpos, MD: Swixx - Honoraria; Takeda - Honoraria; Menarini - Honoraria; Johnson & Johnson - Honoraria; Sanofi - Honoraria; GSK - Honoraria; Forus - Honoraria; Bristol Myers Squibb - Honoraria; Antengene - Honoraria; Pfizer - Honoraria; Amgen - Honoraria; EUSA Pharma - Honoraria; Johnson & Johnson - Research Funding; GSK - Research Funding; Sanofi - Research Funding; Menarini - Research Funding; Menarini - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); EUSA Pharma - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony)